Misplaced Pages

Vepalimomab: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 14:28, 1 April 2020 editFswitzer4 (talk | contribs)Extended confirmed users10,578 editsm added FDA UNII to drug box← Previous edit Revision as of 22:18, 31 December 2020 edit undoOAbot (talk | contribs)Bots441,761 editsm Open access bot: doi added to citation with #oabot.Next edit →
Line 41: Line 41:
| molecular_weight = | molecular_weight =
}} }}
'''Vepalimomab''' is an experimental ] ] intended for the treatment of ]s. It blocks ].<ref>{{cite journal | vauthors = Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T | title = Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis | journal = Basic & Clinical Pharmacology & Toxicology | volume = 96 | issue = 6 | pages = 429–35 | date = June 2005 | pmid = 15910406 | doi = 10.1111/j.1742-7843.2005.pto_05.x }}</ref> Development of the drug was discontinued in 2002.<ref>{{cite web |title=Vepalimomab | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800016990 | publisher = Springer Nature Switzerland AG }}</ref> '''Vepalimomab''' is an experimental ] ] intended for the treatment of ]s. It blocks ].<ref>{{cite journal | vauthors = Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T | title = Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis | journal = Basic & Clinical Pharmacology & Toxicology | volume = 96 | issue = 6 | pages = 429–35 | date = June 2005 | pmid = 15910406 | doi = 10.1111/j.1742-7843.2005.pto_05.x | doi-access = free }}</ref> Development of the drug was discontinued in 2002.<ref>{{cite web |title=Vepalimomab | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800016990 | publisher = Springer Nature Switzerland AG }}</ref>


== References == == References ==

Revision as of 22:18, 31 December 2020

Pharmaceutical compound
Vepalimomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetVAP-1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
  (what is this?)  (verify)

Vepalimomab is an experimental mouse monoclonal antibody intended for the treatment of inflammations. It blocks vascular adhesion protein 1. Development of the drug was discontinued in 2002.

References

  1. Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T (June 2005). "Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis". Basic & Clinical Pharmacology & Toxicology. 96 (6): 429–35. doi:10.1111/j.1742-7843.2005.pto_05.x. PMID 15910406.
  2. "Vepalimomab". AdisInsight. Springer Nature Switzerland AG.
Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)
Antimetabolites
Macrolides/
other IL-2 inhibitors
IMiDs
Intracellular
(reception)
IL-1 receptor antagonists
mTOR
Extracellular
Antibodies
Monoclonal
Serum target
(noncellular)
Cellular
target
Unsorted
Polyclonal
-cept (Fusion)
Unsorted
Monoclonal antibodies for the immune system
Immune system
Human
Mouse
Chimeric
Humanized

Immune activation: Dostarlimab
Other: Ibalizumab

Chimeric + humanized
Interleukin
Human
Humanized
Veterinary
Inflammatory lesions
Mouse
Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: